Ability of flumazenil, butorphanol, and naloxone to reverse the anesthetic effects of oxymorphone-diazepam in dogs

Journal of the American Veterinary Medical Association

Volumn 209, Issue 4, 1996, Pages 776-779

  Lemke, K A ^a,b   Tranquilli, W J ^a   Thurmon, J C ^a   Benson, G J ^a   Olson, W A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; DIAZEPAM; FLUMAZENIL; GLYCOPYRRONIUM BROMIDE; OXYMORPHONE;

ANESTHESIA; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; EXTUBATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; VETERINARY MEDICINE;

ADJUVANTS, ANESTHESIA; ANESTHETICS, COMBINED; ANIMALS; BUTORPHANOL; CROSS-OVER STUDIES; DIAZEPAM; DOGS; DRUG COMBINATIONS; FEMALE; FLUMAZENIL; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OXYMORPHONE; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS; ILEX COOKII;

EID: 0029779686     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bednarski RM. Recent advances in injectable chemical restraint. In: Kirk RW, ed. Current veterinary therapy XI. Philadelphia: WB Saunders Co, 1992;27-31.
2. Reeves JG, Glass PSA. Nonbarbiturate intravenous anesthetics. In: Miller RD, ed. Anesthesia. 3rd ed. New York: Churchill Livingstone Inc, 1990;243-279.
3. Ghonem MM, Dembo JB, Block RI. Time course of antagonism of sedative and amnestic effects of diazepam by flumazenil. Anesthesiology 1989;70:899-904.
4. Sage DJ, Close A, Boas RA. Reversal of midazolam sedation with anexate. Br J Anaesth 1987;59:459-464.
5. Lauven PM, Schwilden H, Stoeckel H. The effects of a benzodiazepine antagonist Ro15-1788 in the presence of stable concentrations of midazolam. Anesthesiology 1985;63:61-64.
6. Greene SA, Moore MP, Keegan RD, et al. Quantitative electroencephalography for measurement of central nervous system responses to diazepam and the benzodiazepine antagonist, flumazenil, in isoflurane-anaesthetized dogs. J Vet Pharmacol Ther 1992;15:259-266.
7. Keegan RD, Greene SA, Moore MP, et al. Antagonism by flumazenil of midazolam-induced changes in quantitative electroencephalographic data from isoflurane-anesthetized dogs. Am J Vet Res 1993;54:761-765.
8. Tranquilli WJ, Gross ME, Thurmon JC, et al. Evaluation of three midazolam-xylazine mixtures. Preliminary trials in dogs. Vet Surg 1990;19:168-172.
9. Gross ME, Tranquilli WJ, Thurmon JC, et al. Yohimbine/ flumazenil antagonism of hemodynamic alterations induced by a combination of midazolam, xylazine, and butorphanol in dogs. J Am Vet Med Assoc 1992;201:1887-1890.
10. Tranquilli WJ, Lemke KA, Williams LL, et al. Flumazenil efficacy in reversing diazepam or midazolam overdose in dogs. J Vet Anesth 1991;19:65-68.
11. Dyson DH, Doherty T, Anderson GI, et al. Reversal of oxymorphone sedation by naloxone, nalmefene, and butorphanol. Vet Surg 1990;19:398-403.
12. McCrackin MA, Harvey RC, Sackman JE, et al. Butorphanol tartrate for partial reversal of oxymorphone-induced postoperative respiratory depression in the dog. Vet Surg 1994;23:67-74.
13. Copland VS, Haskins SC, Patz JD. Naloxone reversal of oxymorphone effects in dogs. Am J Vet Res 1989;50:1854-1858.
14. Dyson DH, Atilola M. A clinical comparison of oxymorphone-acepromazine and butorphanol-acepromazine sedation in dogs. Vet Surg 1992;21:418-421.
15. Sawyer DC, Rech RH, Adams T, et al. Analgesia and behavioral responses of dogs given oxymorphone-acepromazine and meperidine-acepromazine after methoxyflurane and halothane anesthesia. Am J Vet Res 1992;53:1361-1368.
16. Booth NH. Neuroleptanalgesics, narcotic analgesics, and analgesic antagonists. In: Booth NH, McDonald LE, eds. Veterinary pharmacology and therapeutics. 5th ed. Ames, Iowa: Iowa State University Press, 1982;267-296.
17. Zar JH. Multiple comparisons. In: Zar JH, ed. Biostatistical analysis. 2nd ed. Engelwood Cliffs, Calif: Prentice-Hall, 1984;185-205.
18. Haskins SC, Farver TB, Patz JD. Cardiovascular changes in dogs given diazepam and diazepam-ketamine. Am J Vet Res 1986;47: 795-798.
19. Mohler H, Richards JG. The benzodiazepine receptor: a pharmacological control element of brain function. Eur J Anaesthesiol 1988;2:15-25.
20. Pfeffer H, Smyth RD, Pittman KA. Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs. J Pharm Sci 1980;69:801-803.
21. Pace NL, Parrish RG, Lieberman MM. Pharmacokinetics of naloxone and naltrexone in the dog. J Pharmacol Exp Ther 1979;208: 254-256.
22. Loscher W, Frey HH. Pharmacokinetics of diazepam in the dog. Arch Int Pharmacodyn Ther 1981;254:180-195.
23. O'Boyle C, Lambe R, Darragh A, et al. Ro15-1788 antagonizes the effects of diazepam in man without affecting its bioavailability. Br J Anaesth 1983;55:349-355.
24. Sage DJ, Close A, Boas RA. Reversal of midazolam sedation with anexate. Br J Anaesth 1987;59:459-464.
25. Longnecker DE, Grazis PA, Eggers GWN. Naloxone for antagonism of morphine-induced respiratory depression. Anesth Analg 1973;52:447-453.
26. Azar I, Turndorf H. Severe hypertension and multiple atrial premature contractions following naloxone administration. Anesth Analg 1979;58:524-525.
27. Flacke JW, Flacke WE, Williams GD. Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology 1977;47:376-378.
28. Michealis LL, Hickey PR, Clarke TA. Ventricular irritability associated with the use of naloxone hydrochloride. Ann Thorac Surg 1974;18:608-614.
29. Andree RA. Sudden death following naloxone administration. Anesth Analg 1980;59:782-784.
30. Paddleford RR, Short CE. An evaluation of naloxone as a narcotic antagonist in the dog. J Am Vet Med Assoc 1973;163:144-146.
31. Sloan JW, Martin WR, Wala E. Effect of the chronic dose of diazepam on the intensity and characteristics of the precipitated abstinence syndrome in the dog. J Pharmacol Exp Ther 1993;265: 1152-1162.
32. Loscher W, Honack D. Withdrawal precipitation by benzodiazepine receptor antagonists in dogs chronically treated with diazepam or the novel anxiolytic and anticonvulsant beta-carboline abecarnil. Naunyn Schmiedebergs Arch Pharmacol 1992;345:452-460.